HALOZYME THERAPEUTICS, INC. Total Contract Liability
HALOZYME THERAPEUTICS, INC. (HALO) had Total Contract Liability of $31.67 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability $31.67M.
- 2026-03-31: Contract with Customer, Liability $32.95M.
- 2025-12-31: Contract with Customer, Liability $35.48M.
- 2025-09-30: Contract with Customer, Liability $8.37M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-06-30 | $31.67M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $32.95M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $35.48M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $8.37M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $8.37M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $9.21M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $10.34M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $9.13M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $4.86M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $4.59M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $4.05M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $2.92M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $3.10M 10-Q · filed 2023-08-08 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-20 | $5.50M 10-K · filed 2023-02-21 |
| 2021-12-31 | $4.28M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $5.77M 10-K · filed 2021-02-23 | |
| 2020-09-30 | $1.39M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $1.39M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $4.65M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.26M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $4.76M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $8.26M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $8.76M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $9.26M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |